Mumio (Shilajit) is a traditional medicinal drug known and used for hundreds of years. Bladder cancer is one of the most common cancer types and better treatments are needed. This study analysed the in vitro effect of Mumio on urinary bladder cancer cells (T24 and 5637) in comparison to normal uroepithelial cells (SV-HUC1). Cytotoxicity of Mumio was analysed in these cell lines via MTT and real-time cell growth assays as well via the assessment of the cytoskeleton, apoptosis, and cell cycle. Mumio affected the viability of both cell types in a time and concentration dependent manner. We observed a selectivity of Mumio against cancer cells. Cell cycle and apoptosis analysis showed that Mumio inhibited G0/G1 or S phase cell cycle, which in turn induced apoptosis. Our results showed that Mumio was significantly more cytotoxic to urinary bladder cancer cells than to normal cells. These results are promising and indicate Mumio as a great candidate for urinary bladder cancer treatment and further investigations should be performed.
Antineoplastic Agents/pharmacology , Drug Screening Assays, Antitumor/methods , Minerals/pharmacology , Resins, Plant/pharmacology , Urinary Bladder Neoplasms/drug therapy , Actins/biosynthesis , Apoptosis , Carcinoma/drug therapy , Cell Cycle/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival , Cytoskeleton/drug effects , Humans , Tetrazolium Salts/analysis , Thiazoles/analysis
In general, detection of peritoneal carcinomatosis (PC) occurs at the late stage when there is no treatment option. In the present study, we designed novel drug delivery systems that are functionalized with anti-CD133 antibodies. The C1, C2 and C3 complexes with cisplatin were introduced into nanotubes, either physically or chemically. The complexes were reacted with anti-CD133 antibody to form the labeled product of A0-o-CX-chem-CD133. Cytotoxicity screening of all the complexes was performed on CHO cells. Data showed that both C2 and C3 Pt-complexes are more cytotoxic than C1. Flow-cytometry analysis showed that nanotubes conjugated to CD133 antibody have the ability to target cells expressing the CD133 antigen which is responsible for the emergence of resistance to chemotherapy and disease recurrence. The shortest survival rate was observed in the control mice group (K3) where no hyperthermic intraperitoneal chemotherapy procedures were used. On the other hand, the longest median survival rate was observed in the group treated with A0-o-C1-chem-CD133. In summary, we designed a novel drug delivery system based on carbon nanotubes loaded with Pt-prodrugs and functionalized with anti-CD133 antibodies. Our data demonstrates the effectiveness of the new drug delivery system and provides a novel therapeutic modality in the treatment of melanoma.
Cisplatin/administration & dosage , Cisplatin/chemistry , Drug Delivery Systems/methods , Hyperthermia, Induced/methods , Nanotubes, Carbon/chemistry , Peritoneal Neoplasms/therapy , AC133 Antigen , Animals , Antibodies/administration & dosage , Antibodies/chemistry , Antibodies/immunology , Antigens, CD/chemistry , Antigens, CD/immunology , Combined Modality Therapy , Disease Models, Animal , Glycoproteins/chemistry , Glycoproteins/immunology , Immunotoxins/administration & dosage , Immunotoxins/chemistry , Immunotoxins/immunology , Injections, Intraperitoneal , Melanoma, Experimental/drug therapy , Melanoma, Experimental/therapy , Mice , Mice, Inbred C57BL , Peptides/chemistry , Peptides/immunology , Peritoneal Neoplasms/drug therapy , Survival Rate
The drug-carrier system used as innovative haemostatic dressing with oncostatic action is studied. It is obtained from CDDP (cisplatin) doped SWCNT (single walled carbon nanotubes), modified and purified by H2O2 in hydrothermal treatment process. In the in vivo nephron sparing surgery (NSS) study we used 35 BALB/c nude mice with induced renal cancer using adenocarcinoma 786-o cells. Animals were divided into four groups: CDDP(M-), CDDP(M+), CONTROL(M-) and CONTROL(M+). In CDDP(M-) and CDDP(M+) groups we used, intraoperatively, carbon nanotubes filled with cisplatin (CDDP). In CONTROL(M-) and CONTROL(M+) groups carbon nanotubes were used alone. During NSS free margin (M-) or positive margin (M+) was performed. In the CDDP(M-) group, we do not observe local tumor recurrences. In Group CDDP(M+) only one animal was diagnosed with tumor recurrence. In control groups the recurrent tumor formation was observed. In our study, it is shown that CDDP filled SWCNT inhibit cancer recurrence in animal model NSS study, and can be successfully applied as haemostatic dressings for local chemoprevention.
Antineoplastic Agents/pharmacology , Bandages , Hemostatics/pharmacology , Nanotubes, Carbon/chemistry , Animals , Carcinoma, Renal Cell/pathology , Cell Line, Tumor , Cisplatin/pharmacology , Kidney Neoplasms/pathology , Male , Mice, Inbred BALB C , Mice, Nude , Nanotubes, Carbon/ultrastructure , Xenograft Model Antitumor Assays
INTRODUCTION: Alginate scaffolds are widely used in tissue engineering. The aim of this study was to evaluate alginate as a scaffold for 3D cultures of rapidly proliferating cells. MATERIALS AND METHODS: Murine 3T3 fibroblasts were cultured in an alginate scaffold for 30 days. Cells growing in alginate were observed under the inverted microscope. Pathologic examination by hematoxylin and eosin staining was done at the end of the experiment. RESULTS: Migration of rapidly proliferating cells from the 3D scaffold and an inappropriate growth pattern were observed during the experiment. Cells and scaffold did not form a solid graft. CONCLUSIONS: The results obtained in this study indicated that alginate is not a good biomaterial for a durable implant.
Alginates , Cell Division/physiology , 3T3 Cells/cytology , 3T3 Cells/physiology , Animals , Cell Movement , Hepatocytes/cytology , Hepatocytes/physiology , Kinetics , Mice , Tissue Scaffolds
